On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

Efficacy and Safety

Efficacy was evaluated in the POTOMAC study (NCT03528694), a randomized, open-label, multicenter trial that enrolled 1,018 patients with high-risk NMIBC following transurethral resection of bladder tumour. High-risk NMIBC was defined as having one of the following: T1 tumour, Grade 3/high-grade tumour, carcinoma in situ (CIS), or multiple, recurrent, and large tumours. Patients were randomized (1:1:1) to receive either durvalumab every four weeks for 13 cycles plus BCG induction and maintenance, BCG induction and maintenance, or an additional investigational combination regimen.

The major efficacy outcome measure was investigator-assessed disease-free survival (DFS). DFS was defined as the time from the date of randomization until the date of first recurrence of high-risk NMIBC, persistent CIS, muscle invasive bladder cancer, metastatic disease, or death.

A statistically significant improvement in DFS was observed with durvalumab plus BCG induction and maintenance treatment compared to BCG induction and maintenance treatment alone (hazard ratio 0.68 [95% CI: 0.50, 0.93]; two-sided p-value 0.0154; median DFS not reached for either arm).

The prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicities.

Recommended Dosage

The recommended durvalumab dose for patients with a body weight of ≥30 kg is 1,500 mg every four weeks for 13 cycles in combination with BCG induction and maintenance treatment. Treatment should continue until recurrence of high-risk disease, disease progression, unacceptable toxicity, or a maximum of 13 cycles.

Source: FDA